The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis-Reference-Cited by-同舟云学术

The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis

Published:2017-03-01 Issue:4 Volume:176 Page:928-938
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Griffiths C.E.M.¹,Thaçi D.²,Gerdes S.³,Arenberger P.⁴,Pulka G.⁵,Kingo K.⁶,Weglowska J.⁷,Hattebuhr N.⁸,Poetzl J.⁸,Woehling H.⁸,Wuerth G.⁸,Afonso M.⁸,

Affiliation:

1. Dermatology Centre; Salford Royal Hospital; University of Manchester; Manchester Academic Health Science Centre; Manchester U.K.

2. Comprehensive Center for Inflammation Medicine; University Hospital Schleswig-Holstein; Campus Lübeck Lübeck Germany

3. Psoriasis-Center at the Department of Dermatology; Universitaetsklinikum; Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 19 24105 Kiel Germany

4. Department of Dermatology; Charles University Third Medical Faculty and Faculty Hospital Kralovske Vinohrady; Srobarova 50 Prague 10 10034 Czech Republic

5. Grazyna Pulka Specjalistyczny Osrodek ‘ALL-MED’ ul. Sw. Marka 31/IU; ul. Sw. Krzyza 16/14 Krakow 31-023 Poland

6. Dermatology Clinic; Tartu University Hospital; Raja 31 Tartu 50417 Estonia

7. Department of Dermatology; Wojewodzki Szpital Specjalistyczny we Wroclawiu; ul. Kamienskiego 73a Wroclaw 51-124 Poland

8. Global Clinical Development, Biopharmaceuticals; Hexal AG; Industriestraße 25 D 83607 Holzkirchen Germany

Funder

Hexal AG, a Sandoz company

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.15152/fullpdf

Reference32 articles.

1. TNF-mediated inflammatory disease;Bradley;J Pathol,2008

2. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future;Sedger;Cytokine Growth Factor Rev,2014

3. Etanercept as monotherapy in patients with psoriasis;Leonardi;N Engl J Med,2003

4. Mechanisms of action of etanercept in psoriasis;Tan;J Investig Dermatol Symp Proc,2007

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents;Journal of Dermatological Treatment;2023-11-15

2. Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting;BMJ Open;2023-11

3. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review;Dermatology and Therapy;2023-09-14

4. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review;DERMATOLOGY THER;2023

5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12